New heart failure drug shows promise in early trial
NCT ID NCT06142383
First seen Jan 11, 2026 · Last updated May 09, 2026 · Updated 16 times
Summary
This study tested a new medicine called XXB750 in 136 people with heart failure and reduced heart pumping ability. The goal was to see if the drug could lower a key stress marker in the blood and improve symptoms. The trial was stopped early, but the results help researchers understand how this drug might work for heart failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Clinical Trials
Acworth, Georgia, 30101, United States
-
Anderson Medical Research
Ft. Washington, Maryland, 20744, United States
-
Aultman Hospital
Canton, Ohio, 44710, United States
-
Cardiology Partners Clinical Research Institute
Wellington, Florida, 33449, United States
-
Dominion Medical Associates
Richmond, Virginia, 23219, United States
-
Heart Center Research Llc
Huntsville, Alabama, 35801, United States
-
Heart Clinic of Hammond
Hammond, Louisiana, 70403, United States
-
Inpatient Research Clinical LLC
Miami Lakes, Florida, 33014, United States
-
Nature Coast Clinical Research LLC
Inverness, Florida, 34452, United States
-
NexGen Research
Lima, Ohio, 45801, United States
-
Novartis Investigative Site
Blagoevgrad, 270 0, Bulgaria
-
Novartis Investigative Site
Gabrovo, 5300, Bulgaria
-
Novartis Investigative Site
Kyustendil, 2500, Bulgaria
-
Novartis Investigative Site
Pleven, 5800, Bulgaria
-
Novartis Investigative Site
Plovdiv, 4002, Bulgaria
-
Novartis Investigative Site
Sofia, 1233, Bulgaria
-
Novartis Investigative Site
Sofia, 1510, Bulgaria
-
Novartis Investigative Site
Varna, 9010, Bulgaria
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Berlin, 13347, Germany
-
Novartis Investigative Site
Cologne, 51065, Germany
-
Novartis Investigative Site
Gladbeck, 45968, Germany
-
Novartis Investigative Site
Kiel, 24105, Germany
-
Novartis Investigative Site
Ludwigshafen, 67067, Germany
-
Novartis Investigative Site
Papenburg, 26871, Germany
-
Novartis Investigative Site
Schwäbisch Hall, 74523, Germany
-
Novartis Investigative Site
Budapest, Pest County, 1134, Hungary
-
Novartis Investigative Site
Balatonfüred, 8230, Hungary
-
Novartis Investigative Site
Belagavi, Karnataka, 590010, India
-
Novartis Investigative Site
Bikaner, Rajasthan, 334003, India
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Messina, ME, 98125, Italy
-
Novartis Investigative Site
Milan, MI, 20138, Italy
-
Novartis Investigative Site
Pordenone, PN, 33170, Italy
-
Novartis Investigative Site
Roma, RM, 00133, Italy
-
Novartis Investigative Site
Roma, RM, 00168, Italy
-
Novartis Investigative Site
Trieste, TS, 34149, Italy
-
Novartis Investigative Site
Maebashi, Gunma, 371 8511, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 216-8511, Japan
-
Novartis Investigative Site
Sagamihara, Kanagawa, 252-0375, Japan
-
Novartis Investigative Site
Matsumoto, Nagano, 390-8621, Japan
-
Novartis Investigative Site
Lisbon, 1449-005, Portugal
-
Novartis Investigative Site
Vila Nova de Gaia, 4434 502, Portugal
-
Novartis Investigative Site
Bardejov, Slovakia, 085 01, Slovakia
-
Novartis Investigative Site
Košice, Slovakia, 040 01, Slovakia
-
Novartis Investigative Site
Martin, Slovakia, 036 01, Slovakia
-
Novartis Investigative Site
Nitra, Slovakia, 949 11, Slovakia
-
Novartis Investigative Site
Prešov, Slovakia, 080 01, Slovakia
-
Novartis Investigative Site
Svidník, Slovakia, 089 01, Slovakia
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Huelva, Andalusia, 21005, Spain
-
Novartis Investigative Site
Majadahonda, Madrid, 28222, Spain
-
Novartis Investigative Site
Las Palmas GC, 35010, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Taichung, 40447, Taiwan
-
Revival Research Institute
Troy, Michigan, 48084, United States
-
SEC Clinical Research
Dothan, Alabama, 36305, United States
-
Tennessee Center For Clinical Trials
Tullahoma, Tennessee, 37388, United States
-
The Research Group
Lexington, Kentucky, 40503, United States
Conditions
Explore the condition pages connected to this study.